HealthInvestor Executive Moves
Remember me:
HealthInvestor Executive moves The latest appointments in the independent healthcare industry

Syncona Ltd: Danny Bar-Zoha

Syncona Ltd, a healthcare company focused on founding, building and funding global leaders in life sciences, has appointd Danny Bar-Zohar as a partner.

In this role, Danny will  his expertise in clinical development, regulatory environments and medical affairs to help Syncona further build and establish its portfolio of life science companies. 

Danny has almost 15 years of experience in the pharmaceutical and biotechnology sector, having worked at Teva Pharmaceutical Industries and Novartis Pharma after practicing medicine for over a decade. He joins from Novartis where, most recently, he was Global Head of Clinical Development and Analytics, leading all late-stage clinical development across neuroscience, immunology, oncology and ophthalmology, amongst others. During his 7 years at Novartis, Danny held multiple roles including Global Head of Neuroscience Development and Chief Scientific Officer of Novartis Pharma Italy. 

Before joining Novartis, Danny spent 7 years at Teva Pharmaceutical industries Global Innovative Products division where he headed multiple therapy areas and clinical programmes in Neurology. Prior to Teva, Danny had practiced general surgery at Tel-Aviv Sourasky Medical Center, having studied medicine at the Sackler Faculty of Medicine, Tel-Aviv University in Israel. 

Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: “Danny has a wealth of experience in clinical development and we are excited to welcome him to our team. Having served as a surgeon for over a decade, Danny is acutely aware of medicine’s profound impact and we share his drive to improve patient outcomes through transformative treatments. Furthermore, we were particularly drawn to Danny’s deep understanding of the evidence needed to bring high-value therapeutics to patients as this aligns with Syncona’s commercially-oriented found, build, fund strategy.” 

Posted on: 29/05/2020

Latest news stories

The number of people considering paying for private treatment or health insurance has significantly increased since the Covid-19 outbreak, despite the impact of the pandemic on personal finances, according to new research.
Researchers from King’s Business School say that the care sector needs a new model of employment relations to tackle the challenges exposed by the Covid-19 crisis.
The number of deals announced in the global healthcare sector fell by 12% during the week ended June 28, according to GlobalData’s deals database
Health leaders have voiced concerns that the government’s messaging on pandemic mitigation is “clouded in confusion”.
Beckley Psytech has raised £3m of Series A funding to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

HealthInvestor Feature

Consultant profile

Introducing: Kieran Mouser

As Senior Associate of the Finance and IT Practice at Compass Executives, Kieran is responsible for delivery into the investor and privately backed health and social care sectors, specialising in board level CFO, FD, IT and Programme Director mandates.

With a background in boutique finance executive recruitment, Kieran has a successful track record of delivering cross-functional searches for a broad range of clients, with notable placements across a range of assignments. Compass Executives
To find out more about Kieran, or to contact him about new opportunities, please contact or call 7860 355 504.

2019 InvestorPublishing.